Second-generation androgen receptor inhibitors in therapy of non-metastatic castration resistant prostate cancer: role of safety profile and effect on quality of life. (2022). Voprosy Onkologii, 67(2), 217-226. https://doi.org/10.37469/0507-3758-2021-67-2-217-226